While US patients with HER2-positive cancers do not have an available subcutaneous trastuzumab option, Brazil, Canada, and the European Union have an approved product that has been shown in a phase 3 trial to be noninferior to intravenous trastuzumab.
While US patients with HER2-positive cancers do not have an available subcutaneous (SC) trastuzumab option, Brazil, Canada, and the European Union have an approved product that has been shown in a phase 3 trial to be noninferior to intravenous (IV) trastuzumab.
This product has substantial benefits related to patient comfort and provider time, but it also has benefits for trastuzumab’s sponsor, Roche, as there are no approved biosimilars of the SC formulation to compete with this product.
As explained in a paper recently published in Pharmaceutical Medicine, the SC trastuzumab contains the same monoclonal antibody as the intravenous formulation at a dose of 600 mg per 5-mL vial, plus a recombinant human hyaluronidase, to be used every 3 weeks. The hyaluronidase is used to increase the permeability of the extracellular matrix, allowing for administration of higher volumes and enhanced absorption.
The SC formulation had a similar safety profile to the IV formulation in the phase 3 HannaH study, but serious adverse events (AEs) were more common with the SC trastuzumab than the IV product (21.0% vs 12.0%; P value not reported). Antidrug antibodies (ADAs) were reported in 7.1% of patients receiving the IV product and 14.6% of those receiving the SC product, but the elicited ADAs were deemed to have no clinical relevance as they were non-neutralizing and did not impact the pharmacokinetic profile of trastuzumab.
However, one of the main concerns with trastuzumab’s biological activity is its interaction with pertuzumab to treat HER2-positive cancer, and interactions among HER2 receptor, pertuzumab, and trastuzumab—ADA complexes have not yet been fully evaluated. The phase 3 SAPPHIRE study did evaluate the safety, tolerability, and efficacy of IV pertuzumab plus SC trastuzumab and a taxane, but the small population enrolled in the study made it difficult to draw conclusions.
According to the paper’s authors, it also remains unclear whether, in the case of a tumor recurrence, patients who had received the SC product would have more long-lasting memory ADAs, or whether this would impact the safety and efficacy of a subsequent line of treatment using IV trastuzumab and pertuzumab.
Reference
Pimentel FF, Morgan G, Tiezzi DG, de Andrade JM. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceut Med. 2018;32(5):319-325. doi: 10.1007/s40290-018-0247-5.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.